CFO Robert E. Hoffman to deliver company presentation on October 21, 2025VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc.

CCR5 inhibition combined with ICI therapy increased overall survival in patients with mTNBC, with 18% of heavily pretreated mTNBC patients alive after a median of ~60 months. Inhibition of CCR5 by ...

Richard Pestell, M.D., Ph.D., FRCP, AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will deliver a podium presentation on the effects of leronlimab on metastatic triple-negative ...

Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to share the progress we have made in advancing leronlimab as an innovative ...

VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...

SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of CytoDyn Inc. (OTC: CYDY) relating to possible ...

SAN DIEGO & VANCOUVER, Wash.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of CytoDyn Inc. (OTC: CYDY) filed a class action complaint against the Company and its ...

VANCOUVER, Washington, July 12, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the ...

VANCOUVER, Washington, April 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ...

Auris Medical Holding Ltd. EARS, CytoDyn Inc. CYDY and Prometheus Biosciences, Inc. RXDX are among the biggest movers in the biopharma space Thursday. ‘Buy The Rumor' Moment For Auris: Auris, a ...